OptiBiotix Health PLC Exercise of Warrants (7921S)
March 13 2019 - 11:42AM
UK Regulatory
TIDMOPTI
RNS Number : 7921S
OptiBiotix Health PLC
13 March 2019
OptiBiotix Health plc
("OptiBiotix")
Exercise of Warrants and Issue of Equity
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol and diabetes, received notification on 12 March 2019
for the exercise of warrants over 708,325 ordinary shares in the
Company at an exercise price of 8 pence per share providing the
Company with proceeds of GBP56,666.
Application will be made to the London Stock Exchange to admit
the 708,325 new ordinary shares to trading on AIM. Admission of the
new ordinary shares is expected to occur on or around 19 March
2019. The new ordinary shares will rank pari passu with the
existing ordinary shares
For the purpose of the Disclosure and Transparency Rules,
following the issue of shares detailed above the enlarged issued
share capital of the Company will comprise 85,440,551 ordinary
shares of 2p each. The Company does not hold any ordinary shares in
treasury. The above figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company, under the Disclosure and Transparency
Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 and the person who arranged
for release of this announcement on behalf of the Company was
Stephen O'Hara, Chief Executive Officer.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEGGUBWWUPBGAW
(END) Dow Jones Newswires
March 13, 2019 11:42 ET (15:42 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024